相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination
Margherita Rosati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet et al.
CLINICAL MICROBIOLOGY AND INFECTION (2022)
Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period
Ji Yeun Kim et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
Ital Nemet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Covid-19: Fourth vaccine doses-who needs them and why?
Gareth Iacobucci
BMJ-BRITISH MEDICAL JOURNAL (2022)
Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel
Jennifer Kertes et al.
EMERGING INFECTIOUS DISEASES (2022)
COVID-19-neutralizing antibodies predict disease severity and survival
Wilfredo F. Garcia-Beltran et al.
CELL (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Alasdair P S Munro et al.
LANCET (2021)
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y. Tartof et al.
LANCET (2021)
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
Noam Barda et al.
LANCET (2021)
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
Matan Levine-Tiefenbrun et al.
NATURE MEDICINE (2021)
Waning Immunity after the BNT162b2 Vaccine in Israel
Yair Goldberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
BNT162b2 Vaccine Booster and Mortality Due to Covid-19
Ronen Arbel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Einav G. Levin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
Rishi R. Goel et al.
SCIENCE (2021)
Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?
Gaurav Joshi et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers
Jean-Louis Bayart et al.
VACCINES (2021)
BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study
Francesco Bianchi et al.
VACCINES (2021)
Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study
Sergio Salmeron Rios et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2021)
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Eric J. Haas et al.
LANCET (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
David S. Khoury et al.
NATURE MEDICINE (2021)
Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
Evangelos Terpos et al.
LIFE-BASEL (2021)
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
Evangelos Terpos et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data
Christophe Paris et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
Emma C. Wall et al.
LANCET (2021)
COVID-19 vaccine equity and booster doses
LANCET INFECTIOUS DISEASES (2021)
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Yinon M. Bar-On et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
S. J. Thomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
Pinja Jalkanen et al.
NATURE COMMUNICATIONS (2021)
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
Evangelos Terpos et al.
CELLS (2021)
Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
Paul Naaber et al.
LANCET REGIONAL HEALTH-EUROPE (2021)
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
John S. Tregoning et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp et al.
SCIENCE (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2
Yi Zhang et al.
NATURE COMMUNICATIONS (2020)
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
K. Ewer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)